Technische Universität München

The Entrepreneurial University

Liver function disturbances and diseases due to AAS treatment are mainly based on the administration of 17-α-alkylated steroids (e.g. methyltestosterone, oxymetholone, fluoxymesterone, norethandrolone and metandienone). These liver disorders are e.g. biliary stasis, cholestatsis, peliosis hepatis and hepatomas.
Furthermore, investigations reported a lowering of high-density lipoprotein (the “good” one), an increasing of low-density lipoprotein (the “bad” one) and atherogenic-promoting apolipoprotein A. These side-effects are usually reversible upon discontinuation.